Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KHK | P50053 | 3/20 | 1.00 |
| ▸ | IRAK4 | Q9NWZ3 | 11/20 | 0.65 |
| ▸ | GSK3B | P49841 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.45 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.45 |
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.43 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20500059 | 1.00 | KHK (1.00) | KHKIRAK4GSK3BKCNH2DYRK1A | |
| SCHEMBL23711780 | 0.86 | KHK (1.00) | KHKIRAK4NR3C1LRRK2 | |
| SCHEMBL31279526 | 0.86 | KHK (1.00) | KHKIRAK4NR3C1LRRK2 | |
| SCHEMBL23711761 | 0.81 | KHK (0.67) | KHKIRAK4LRRK2 | |
| SCHEMBL31278702 | 0.81 | KHK (0.67) | KHKIRAK4LRRK2 | |
| SCHEMBL17441414 | 0.79 | IRAK4 (1.00) | KHKIRAK4 | |
| SCHEMBL24851437 | 0.78 | KHK (0.63) | KHKNR3C1 | |
| SCHEMBL23711758 | 0.78 | KHK (0.63) | KHKIRAK4LRRK2FFAR4 | |
| SCHEMBL31279250 | 0.78 | KHK (0.63) | KHKIRAK4LRRK2FFAR4 | |
| SCHEMBL22126706 | 0.76 | KHK (0.61) | KHKIRAK4NR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250177348-A1 | Methods for Fructokinase Meditation of Alcohol Craving and Alcohol Induced Liver Disease | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE | 2025-06-05 | — | — | US | disclosed |
| US-12161621-B2 | Methods for fructokinase mediation of alcohol craving and alcohol induced liver disease | THE REGENTS OF THE UNIVERSITY OF COLORADO | 2024-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12161621-B2 | Methods for fructokinase mediation of alcohol craving and alcohol induced liver disease | KHK, GCK, FN3K | KHK 1/4885IRAK4 557/4885GSK3B 835/4885 |
| US-20250177348-A1 | Methods for Fructokinase Meditation of Alcohol Craving and Alcohol Induced Liver Disease | KHK, GCK, FN3K | KHK 1/4885IRAK4 757/4885GSK3B 514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.